<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Mooney, Janice</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Guidelines for the Management of Primary Systemic Vasculitis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">29-29</style></pages><abstract><style  face="normal" font="default" size="100%">Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) comprises a group of rare, potentially life-threatening conditions that can be fatal if untreated. These diseases include granulomatosis with polyangiitis, (previously known as Wegener granulomatosis), Churg-Strauss syndrome, and microscopic polyangiitis. These complex conditions are characterized by systemic illness and multisystem disease, with vasculitis that can lead to aneurysm formation, hemorrhage, and infarction [Watts RA, Scott DG. Curr Opin Rheumatol 2003]. This article discusses the management of AAV.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>